KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

NCT05985707 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Colorectal Cancer
HER2-positive Biliary Tract Cancer

Interventions

DRUG: KN026
DRUG: KN046
DRUG: XELOX

Sponsor

Peking University Cancer Hospital & Institute